Skip to main content
OpenTrials

Clinical trial condition

Neuroectodermal Tumors, Primitive, Peripheral

Explore clinical trials studying Neuroectodermal Tumors, Primitive, Peripheral. Study availability and eligibility vary by location and protocol.

501 public trials 99 recruiting studies
Refine in advanced search Browse all conditions

Neuroectodermal Tumors, Primitive, Peripheral trial results

Completed

Biomarkers in Tumor Tissue Samples From Patients With Newly Diagnosed Neuroblastoma or Ganglioneuroblastoma

NCT00904241

Conditions
Ganglioneuroblastoma, Localized Resectable Neuroblastoma, Localized Unresectable Neuroblastoma, +13 more
Locations
  • Children's Hospital of Alabama Birmingham, Alabama, United States
  • University of Alabama at Birmingham Cancer Center Birmingham, Alabama, United States
  • USA Health Strada Patient Care Center Mobile, Alabama, United States
  • Providence Alaska Medical Center Anchorage, Alaska, United States
View all 259 locations
View Trial Details
Completed

Dinutuximab, Sargramostim, and Combination Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma

NCT03786783

Conditions
Ganglioneuroblastoma, High Risk Neuroblastoma, Neoplasms, +9 more
Locations
  • Children's Hospital Los Angeles Los Angeles, California, United States
  • Children's National Medical Center Washington D.C., District of Columbia, United States
  • Dana-Farber Cancer Institute Boston, Massachusetts, United States
  • NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center New York, United States
View Trial Details
Completed

Activity Study of Bevacizumab With Temozolomide ± Irinotecan for Neuroblastoma in Children

NCT02308527

Conditions
Neoplasms, Neoplasms by Histologic Type, Neoplasms, Germ Cell and Embryonal, +7 more
Locations
  • St Anna Children's Hospital and CCRI/Studies and Statistics Vienna, Austria
  • University Hospital Ghent, Belgium
  • University Hospital Rigshospitalet Copenhagen, Denmark
  • Hopital des Enfants Toulouse, France
View Trial Details
Completed

A Clinical Study Evaluating the Safety of Peptide Receptor Radionuclide Therapy (PRRT) With 177Lu-DOTA0-Tyr3-Octreotate in Children With Refractory or Recurrent Neuroblastoma Expressing Somatostatin Receptors.

NCT03966651

Conditions
Neoplasms, Neoplasms by Histologic Type, Neoplasms, Germ Cell and Embryonal, +7 more
Locations
  • CHU Angers Angers, France
  • CHU Besançon Besançon, France
  • CHU Pellegrin Bordeaux, France
  • CHU Dijon Dijon, France
View all 14 locations
View Trial Details
Completed

N2001-02: I-MIBG With Intensive Chemotherapy and Autologous Stem Cell Rescue for High-Risk Neuroblastoma

NCT00253435

Conditions
Neoplasms, Neoplasms by Histologic Type, Neoplasms, Germ Cell and Embryonal, +7 more
Locations
  • Childrens Hospital Los Angeles Los Angeles, California, United States
  • Lucile Packard Children's Hospital at Stanford University Medical Center Palo Alto, California, United States
  • UCSF Helen Diller Family Comprehensive Cancer Center San Francisco, California, United States
  • AFLAC Cancer Center and Blood Disorders Service of Children's Healthcare of Atlanta - Egleston Campus Atlanta, Georgia, United States
View all 15 locations
View Trial Details
Completed

N2000-01: Double Infusion of Iodine I 131 Metaiodobenzylguanidine Followed by Autologous Stem Cell Transplantation

NCT00083135

Conditions
Neoplasms, Neoplasms by Histologic Type, Neoplasms, Germ Cell and Embryonal, +7 more
Locations
  • Children's Hospital Los Angeles Los Angeles, California, United States
  • UCSF Comprehensive Cancer Center San Francisco, California, United States
  • Indiana University Cancer Center Indianapolis, Indiana, United States
  • Children's Hospital Boston Boston, Massachusetts, United States
View Trial Details
Completed

N2003-01: Irinotecan, Temozolomide, and Cefixime in Treating Young Patients With Recurrent or Resistant Neuroblastoma

NCT00093353

Conditions
Chemically-Induced Disorders, Diarrhea, Drug-Related Side Effects and Adverse Reactions, +14 more
Locations
  • Children's Hospital Los Angeles Los Angeles, California, United States
  • Lucile Packard Children's Hospital at Stanford University Medical Center Palo Alto, California, United States
  • UCSF Comprehensive Cancer Center San Francisco, California, United States
  • AFLAC Cancer Center and Blood Disorders Service of Children's Healthcare of Atlanta - Egleston Campus Atlanta, Georgia, United States
View all 13 locations
View Trial Details
Completed

N2004-06: Irinotecan and Vincristine With 131I-MIBG Therapy for Resistant/Relapsed High-Risk Neuroblastoma

NCT00509353

Conditions
Neoplasms, Neoplasms by Histologic Type, Neoplasms, Germ Cell and Embryonal, +7 more
Locations
  • Childrens Hospital Los Angeles Los Angeles, California, United States
  • Lucile Packard Children's Hospital at Stanford University Medical Center Palo Alto, California, United States
  • UCSF Helen Diller Family Comprehensive Cancer Center San Francisco, California, United States
  • AFLAC Cancer Center and Blood Disorders Service of Children's Healthcare of Atlanta - Egleston Campus Atlanta, Georgia, United States
View Trial Details
Completed

N2004-04: Fenretinide LXS in Treating Patients With Recurrent, Refractory, or Persistent Neuroblastoma

NCT00295919

Conditions
Neoplasms, Neoplasms by Histologic Type, Neoplasms, Germ Cell and Embryonal, +7 more
Locations
  • Childrens Hospital Los Angeles Los Angeles, California, United States
  • Lucile Packard Children's Hospital at Stanford University Medical Center Palo Alto, California, United States
  • UCSF Helen Diller Family Comprehensive Cancer Center San Francisco, California, United States
  • AFLAC Cancer Center and Blood Disorders Service of Children's Healthcare of Atlanta - Scottish Rite Campus Atlanta, Georgia, United States
View Trial Details

Related conditions